MannKind Corp. (MNKD) said it has partnered with NRx Pharmaceuticals (NRXP) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI or aviptadil, a synthetic form of human Vasoactive Intestinal Peptide - an endogenous substance produced by the body that helps protect cells against inflammatory conditions.
An intravenous formulation of ZYESAMI is currently in clinical trials, having been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Critical COVID-19 with Respiratory Failure.
MannKind noted that it will begin exploring formulation potential at its research and manufacturing facility located in Danbury, Conn., which features a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. It has sufficient filling capacity to produce more than 300 million cartridges of inhaled drug annually.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.